{"organizations": [], "uuid": "c8bdff5bd5c13aa8cad5ae444ceee55cbbdb86e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/06/globe-newswire-cymabay-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-thursday-march-15.html", "country": "US", "domain_rank": 767, "title": "CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-06T16:00:00.000+02:00", "replies_count": 0, "uuid": "c8bdff5bd5c13aa8cad5ae444ceee55cbbdb86e2"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/06/globe-newswire-cymabay-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-thursday-march-15.html", "ord_in_thread": 0, "title": "CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15", "locations": [], "entities": {"persons": [], "locations": [{"name": "newark", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "cymabay therapeutics, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEWARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.\nConference Call Details\nTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13676717. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events .\nAbout CymaBay\nCymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARÎ´ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.\nFor additional information about CymaBay visit www.cymabay.com .\nContact:\nHans Vitzthum\nLifeSci Advisors, LLC\n212-915-2568\nHans@LifeSciAdvisors.com\nSource:CymaBay Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=ozxAZiHA70WkswcsDpG_GbdfvMjZzNNEBtlAwao6CAm89O1S_bqLFBz26YnpWFPl8JkZXSETNCe6RTf8_nfiSq9Nsqoe3hISvIStcYlRPo4=", "https://www.globenewswire.com/Tracker?data=GjV7Cxe7muaNHy1my2n1H7hscoqw9J6uBRh5ZLKBmDxnqhjySmopNptgtjsTIgjpn81AgsWMRBehnppKCyQUvQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/4ae714bc-fc58-4a8c-94eb-53e0b0c13a01", "http://ir.cymabay.com/events", "https://www.globenewswire.com/Tracker?data=XqFr9FCJHluNFP_vfT-G5xH6hvzPCQU5M9HdbdWyRSVbcq4OrFASB6EJIBaCX2gL6znBNCy_FtZqrO8svZ8jiSyAXgLOnoO58MslwByE2Tw="], "published": "2018-03-06T16:00:00.000+02:00", "crawled": "2018-03-06T18:19:01.062+02:00", "highlightTitle": ""}